Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study.

Kerri BeckmannHans GarmoBertil LindahlLars HolmbergPär StattinJan AdolfssonJ Kennedy CruickshankMieke Van Hemelrijck

Published in: Prostate cancer and prostatic diseases (2020)

PCa risk was reduced among men exposed to the diuretic spironolactone. Further investigation of spironolactone's potential chemopreventive effects is warranted.

Keyphrases

prostate cancer
middle aged
benign prostatic hyperplasia
human health
risk assessment